Shots: 

• GAIN JPAC is an emerging platform where leaders in aesthetics convene to share knowledge and advance patient treatment and safety 

• PharmaShots hosted Gerry Muhle, Head of Global Product Strategy at Galderma, who discussed the ‘Next by Galderma’ report, providing insights into the future of the aesthetics market and helping professionals better understand patient and consumer needs 

• While addressing ‘ethics in aesthetics,’ Gerry highlighted the next-generation neuromodulator Relfydess, which recently received approval in five European markets.   

Saurabh: What is GAIN? What is the primary agenda of the event?  

Gerry: The Galderma Aesthetic Injector Network (GAIN) is a unique community of like-minded aesthetic professionals who are keen to learn and grow. Its main aim is to encourage and facilitate knowledge sharing to ultimately improve the safety and treatment experience of patients and aesthetic professionals themselves. Galderma hosts local, regional, and global training events, like GAIN JPAC, where aesthetic professionals can learn from renowned experts through presentations, live demonstrations, case sharing, panel discussions and more. GAIN JPAC, specifically, focused on the six trends identified in the ‘NEXT by Galderma’ report and how they will shape the future of aesthetics – globally and in Asia-Pacific – with an extensive agenda that spanned two days.   

Saurabh: What is the idea behind the ‘Next by Galderma’ report? Can you give a gist of the major trends discussed in the same?  

Gerry: As the pure-play dermatology category leader, we feel a responsibility to keep driving the industry forward. That’s why we conceived the ‘NEXT by Galderma’ report, to share insights anticipating the future of the market and aiming to empower aesthetic professionals by enhancing their understanding of patient and consumer needs. Over a year’s worth of research went into this groundbreaking report, which we conducted in collaboration with a number of renowned experts. We identified the future trends to be: 

• Proactive Beauty: An increased shift toward early intervention on ageing. 

• Mindful Aesthetics: The prioritization of products with minimal environmental impact that align with patients’ ethical values and provide natural-looking results. 

• Fast Aesthetics: Using aesthetics to mimic the latest fast-moving trends. 

• Beauty Fandom: A reflection of patients’ fascination with niche idolization—from cultural icons to digital filters, anime, and beyond—which is leading to a desire for metamorphosis. 

• Expressionality: A celebration of the empowerment that comes from creating and enhancing one’s identity with aesthetics. 

• Cancelling Age: We are cancelling expectations of what certain ages “should look like”, as consumers employ aesthetics to express their ageless attitude.  

Saurabh: Asia-Pacific has proved to be one of the major markets in the aesthetic domain. Which recent successes strengthened Galderma's position in this segment? How do you envision the future of the aesthetic market?  

Gerry: We have had multiple successes in the Asia-Pacific region already this year, where sales have fueled our strong performance across product categories. This includes key product milestones from our leading aesthetic portfolio, including the launch of Restylane® VOLYME in China, Restylane® EYELIGHT in Korea and Alastin Skincare® in Australia, plus the approvals of RelfydessTM (RelabotulinumtoxinA) in Australia and Sculptra® in China. We expect to see the aesthetic market continue to grow globally, as well as in Asia-Pacific, where the dermatology market has remained on a consistent growth trajectory with high demand for premium, science-based products.   

Saurabh: Relfydess and Sculptra are recently approved in Australia and China. Can we hope to see more launches by the end of the year?  

Gerry: We are proud to have made such significant progress with multiple approvals and launches this year, including the first approvals for our next-generation neuromodulator RelfydessTM in five European markets, following the successful completion of the European decentralized review procedure, and in Australia. We are excited for more to come for Relfydess and for other products across our innovative aesthetic portfolio.   

Saurabh: One of the topics at the recent JPAC edition of GAIN included ‘ethics in aesthetics’. Can you tell us more about it?  

Gerry: We understand the importance of supporting aesthetic professionals in maintaining ethical standards in their practice to ultimately ensure the satisfaction and safety of their patients. Aesthetic procedures have a profound impact on people’s lives, and knowledge and education play a key role in steering toward positive outcomes. That’s why we aim to provide the right information, training, and products, including through GAIN, in order to: 

• grow understanding of our products and their safe and effective use. 

• advance injector skills to ensure the best possible outcomes for patients. 

• educate aesthetic professionals on upcoming trends, needs, innovations, and topics we feel are key in practice. 

Image Source: Canva 

About the Author: 

Gerry Muhle 

Gerry Muhle in his role as Head of Global Product Strategy at Galderma, leads the overall strategy, performance and development for all business units at Galderma globally. Including aesthetics, therapeutic dermatology and dermatologic skincare. Bringing close to 30 years of experience in healthcare, with extensive international franchise experience as a senior leader for large marketing and cross-functional commercial businesses. 

Prior to joining Galderma, Gerry was the Vice President & Head of International Strategic Marketing – Aesthetics at Allergan/AbbVie, delivering large-scale International digital transformation and consumer campaigns and leading many aesthetics launches across the world. Other senior leadership positions included roles in marketing and commercial strategy at Allergan and GlaxoSmithKline. Prior to working in pharmaceuticals, Gerry worked as a molecular geneticist primarily in the area of cardiovascular genetics. 

Related Post: Fostering Safe AI Use: Jay Anders from Medicomp in a Riveting Conversation with PharmaShots